TEVA (Teva) מקדם שווי פעילות להכנסות

The EV/Sales multiple history demonstrates the position of Teva Pharmaceutical Industries (TEVA) as a generics leader relying on mass production and global demand. However, massive debt and ongoing litigation are constraining operational growth. The transition toward biosimilars and branded products is helping Teva Pharmaceutical Industries (TEVA) overcome price dumping. The value of 3403.84 determines the latest enterprise value to revenue metric, excluding debt.
פילוחי מדדים פיננסיים ומדדי שוק עבור Teva Pharmaceuticals (TEVA)

For Teva Pharmaceutical Industries (TEVA), burdened by debt obligations and litigation risks, this indicator becomes a critical filter for assessing the business's real value. The metric compares the enterprise value (EV), including debt, with annual revenue, eliminating the impact of capital structure on the result. Analysis of the EV/Sales valuation chart allows for the determination of whether the asset is overbought amid regulatory pressure and pricing competition in the generics sector.